-
Tytuł:
-
Clinical experience of growth hormone replacement for pediatric intracranial germ cell tumor.
-
Autorzy:
-
Chiba K; Department of Neurosurgery, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan.
Aihara Y; Department of Neurosurgery, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan. .
Kawamata T; Department of Neurosurgery, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan.
-
Źródło:
-
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery [Childs Nerv Syst] 2020 Aug; Vol. 36 (8), pp. 1755-1760. Date of Electronic Publication: 2020 Feb 27.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Berlin : Springer International, c1985-
-
MeSH Terms:
-
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/drug therapy
Human Growth Hormone*
Neoplasms, Germ Cell and Embryonal*/diagnostic imaging
Neoplasms, Germ Cell and Embryonal*/drug therapy
Adolescent ; Body Height ; Child ; Female ; Growth Disorders/drug therapy ; Growth Disorders/etiology ; Growth Hormone/therapeutic use ; Humans ; Neoplasm Recurrence, Local ; Placenta ; Pregnancy ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: Children; Germ cell tumors; Growth hormone; Short stature
-
Substance Nomenclature:
-
12629-01-5 (Human Growth Hormone)
9002-72-6 (Growth Hormone)
-
Entry Date(s):
-
Date Created: 20200229 Date Completed: 20210621 Latest Revision: 20210621
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00381-020-04549-y
-
PMID:
-
32108244
-
Purpose: Intracranial germ cell tumors (IGCTs) account for 8-15% of brain tumors in children in Eastern Asia and typically occur at the age of puberty. Recently, adjuvant therapy has been modified to ameliorate post-treatment complications such as cognitive dysfunction, in patients with IGCT. However, endocrine problems remain to be resolved. There is reluctance to use growth hormone (GH) at an early stage after treatment for IGCT because of the risk of tumor recurrence; however, GH replacement must be administered before the onset of puberty in children with short stature. There is little guidance on this issue due to a lack of literature on the risks of GH replacement therapy in patients with IGCT. This study aimed to evaluate the safety of GH replacement.
Methods: In this retrospective study, 6 patients with IGCT who were under the age of 18 years when they started GH replacement therapy were reviewed. Histopathological analysis and/or analysis of tumor markers was used to confirm a diagnosis.
Results: All six cases who underwent GH replacement therapy showed no recurrence. GH replacement therapy was administered in 5 patients for short stature and all achieved a height within ± 2.0 standard deviation.
Conclusion: GH replacement for children with IGCT was safe in our case series. Placental alkaline phosphatase levels in cerebrospinal fluid can be used to facilitate the decision on when to initiate GH replacement.